VANCOUVER, May 19, 2020 /CNW/ - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN;
OTCQX:IMLFF), a clinical stage pharmaceutical company developing
medications targeting diseases with high unmet medical need and
leading the way in the clinical development of cannabinol ("CBN"),
today announced the filing of a key Patent Cooperation Treaty
("PCT") patent application directed to the Company's biosynthesis
platform technology for the manufacturing of pharmaceutical-grade
cannabinoids.
The PCT patent application entitled "Compositions and Methods
for Biosynthesis of Terpenoids or Cannabinoids in a Heterologous
System" was initially filed as two separate United States
Provisional Patent applications and further addresses the
enablement and maximization of cannabinoid production through
optimization of the precursor substrates needed to support specific
cannabinoid synthesis.
"This PCT filing is on schedule following our previously filed
provisional patent application submissions last year," stated
Eric Hsu, PhD, InMed's Senior Vice
President, Preclinical Research and Development. Dr. Hsu added, "We
continue to pursue our strategy of aggressively protecting our
ongoing developments in our pharmaceutical grade cannabinoid
manufacturing program."
The PCT is an international patent law treaty, which provides a
unified procedure for filing patent applications to protect
inventions in each of its member states. There are 151 member
countries within the PCT, enabling near-global patent coverage
through successful patent prosecution in the
U.S., Japan, Europe, Canada, Australia, New
Zealand, China, Brazil, Russia, India, as well
as many others.
About InMed: InMed Pharmaceuticals is a clinical stage
pharmaceutical company developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol (CBN), in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines. For
more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: leading the way in the clinical
development of cannabinol ("CBN"); a PCT filing providing
intellectual and commercial protection; developing a pipeline of
cannabinoid-based medications in diseases with high unmet medical
need; and delivering new therapeutic alternatives to patients that
may benefit from cannabinoid-based medicines.
With respect to the forward-looking information contained in
this news release, InMed has made numerous assumptions regarding,
among other things: the effectiveness of patent protection; demand
for InMed's products; and continued economic and market stability.
While InMed considers these assumptions to be reasonable, these
assumptions are inherently subject to significant business,
economic, competitive, market and social uncertainties and
contingencies.
Additionally, there are known and unknown risk factors which
could cause InMed's actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include, among
others: the outbreak and impact of COVID-19 may worsen; PCT filings
may not provide the Company with intellectual and commercial
protection; InMed may not be able to advance its other product
candidates on a timely basis, or at all; regulatory filings may not
be filed or approved on a timely basis, or at all; economic or
market conditions may worsen; InMed's proprietary biosynthesis
manufacturing process and drug development programs may not deliver
the expected level of results; and InMed may not be able to provide
new therapeutic alternatives that benefit patients via
cannabinoid-based medicines. A more complete discussion of the
risks and uncertainties facing InMed is disclosed in InMed's most
recent Annual Information Form and other continuous disclosure
filed with Canadian securities regulatory authorities on SEDAR at
www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.NEITHER THE TORONTO STOCK
EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR
ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.
View original
content:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-continues-to-strengthen-biosynthesis-patent-family-301061063.html
SOURCE InMed Pharmaceuticals Inc.